Silo Pharma’s SPC-15 Intranasal PTSD Program Advances Under 505(b)(2) Pathway After Executive Order
Silo Pharma’s lead SPC-15 intranasal PTSD treatment is advancing under a 505(b)(2) pathway following President Trump’s April 18 executive order to accelerate psychedelic therapy research. The therapy’s rapid nose-to-brain formulation and Columbia University-licensed IP position the company to benefit from streamlined federal regulatory support.
1. Regulatory Catalysts
On April 18, President Trump signed an executive order directing federal agencies to fast-track research and patient access for psychedelic-based therapies. This directive could accelerate Silo Pharma’s engagement with the FDA and shorten review times for its SPC-15 intranasal PTSD program.
2. SPC-15 Program Details
SPC-15 is designed as a novel serotonin 4 (5-HT4) receptor agonist administered via a nose-to-brain delivery system for rapid central nervous system uptake. The program leverages intellectual property licensed from Columbia University and is advancing under a 505(b)(2) regulatory pathway with an optimized intranasal device partnership.
3. Potential Market Impact
The global mental health therapeutics market is expanding, with millions suffering from PTSD annually and growing openness to psychedelic-derived treatments. Silo Pharma’s clinically grounded, delivery-optimized approach could capture significant market share if regulatory momentum translates into accelerated clinical trials and commercialization.